


# PRODUCT INFORMATION



## Ro 3306

Item No. 15149

**CAS Registry No.:** 872573-93-8  
**Formal Name:** 5Z-(6-quinolinylmethylene)-2-  
[(2-thienylmethyl)amino]-4(5H)-  
thiazolone  
**MF:** C<sub>18</sub>H<sub>13</sub>N<sub>3</sub>OS<sub>2</sub>  
**FW:** 351.4  
**Purity:** ≥95%  
**UV/Vis.:** λ<sub>max</sub>: 206, 238, 284, 346 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Ro 3306 is supplied as a crystalline solid. A stock solution may be made by dissolving the Ro 3306 in the solvent of choice, which should be purged with an inert gas. Ro 3306 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of Ro 3306 in these solvents is approximately 20 mg/ml.

Ro 3306 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, Ro 3306 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Ro 3306 has a solubility of approximately 0.25 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Cyclin-dependent kinase 1 (Cdk1) complexes with different cyclins, with the cyclin determining substrate specificity. Ro 3306 is a cell-permeable, reversible inhibitor of Cdk1, showing preference for Cdk1/cyclin B1 (K<sub>i</sub> = 35 nM) over Cdk1/cyclin A (K<sub>i</sub> = 110 nM), two CDK complexes which regulate cell cycling.<sup>1</sup> It also inhibits Cdk2 (K<sub>i</sub> = 340 nM), PKCδ (K<sub>i</sub> = 318 nM), and serum- and glucocorticoid-induce kinase (K<sub>i</sub> = 497 nM) but not Cdk4.<sup>1</sup> Through its effects on Cdk1, Ro 3306 reversibly arrests proliferating cells at the G<sub>2</sub>/M phase border, allowing cell synchronization without the use of microtubule poisons.<sup>2</sup> Prolonged treatment of cells with Ro 3306 induces apoptosis and this can be augmented in acute myeloid leukemia cells by stimulating p53 activity with nutlin-3.<sup>3</sup>

### References

1. Vassilev, L.T., Tovar, C., Chen, S., *et al.* Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. *Proc. Natl. Acad. Sci. USA* **103**(28), 10660-10665 (2006).
2. Vassilev, L.T. Cell cycle synchronization at the G<sub>2</sub>/M phase border by reversible inhibition of CDK1. *Cell Cycle* **5**(22), 2555-2556 (2006).
3. Kojima, K., Shimanuki, M., Shikami, M., *et al.* Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. *Cancer Sci.* **100**(6), 1128-1136 (2009).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/01/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM